IQVIA Holdings Inc. (IQV)

125.55
0.48 0.38
NYSE : Health Services
Prev Close 125.07
Open 125.22
Day Low/High 124.64 / 127.66
52 Wk Low/High 91.57 / 128.40
Volume 1.51M
Avg Volume 1.29M
Exchange NYSE
Shares Outstanding 202.59M
Market Cap 25.65B
EPS 6.00
P/E Ratio 21.86
Div & Yield N.A. (N.A)

Latest News

Medytox Selects IQVIA's Enterprise Quality Management Platform, Including SmartSolve®, For Quality And Compliance Management

Medytox Selects IQVIA's Enterprise Quality Management Platform, Including SmartSolve®, For Quality And Compliance Management

IQVIA™ (NYSE: IQV) today announced that the global biopharmaceutical company Medytox has selected IQVIA's Enterprise Quality Management Solutions (EQMS) platform for quality and compliance management.

IQVIA's Jon Resnick Honored On 2018 PharmaVOICE 100 List

IQVIA's Jon Resnick Honored On 2018 PharmaVOICE 100 List

IQVIA (NYSE:IQV) today announced that Jon Resnick, IQVIA's president, Real-World & Analytics Solutions, has been named to PharmaVOICE magazine's annual list of the 100 most influential and inspiring individuals within the life sciences industry.

IQVIA Holdings Becomes #193 Most Shorted S&P 500 Component, Replacing Xylem

IQVIA Holdings Becomes #193 Most Shorted S&P 500 Component, Replacing Xylem

The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

IQVIA Reports Second-Quarter 2018 Results And Raises Full-Year 2018 Revenue And Profit Guidance

IQVIA Reports Second-Quarter 2018 Results And Raises Full-Year 2018 Revenue And Profit Guidance

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2018.

IQVIA To Announce Second-Quarter 2018 Results On July 24, 2018

IQVIA To Announce Second-Quarter 2018 Results On July 24, 2018

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), will announce its second-quarter 2018 financial results before the market opens on Tuesday, July 24, 2018.

IQVIA Launches A Transformative Suite Of Virtual Research Solutions

IQVIA Launches A Transformative Suite Of Virtual Research Solutions

IQVIA (NYSE:IQV) announced today the launch of Virtual Research Solutions, a new suite of technology-led study options offering advances in patient-centric trial design and execution.

Analyst Favorites With Strong Buyback Activity: IQVIA Holdings Ranks As A Top Pick

Analyst Favorites With Strong Buyback Activity: IQVIA Holdings Ranks As A Top Pick

A study of analyst recommendations at the major brokerages shows that IQVIA Holdings Inc is the #51 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

IQVIA Announces Pricing Of Secondary Public Offering

IQVIA Announces Pricing Of Secondary Public Offering

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment...

IQVIA Announces Launch Of Secondary Public Offering And Repurchase Of Common Stock

IQVIA Announces Launch Of Secondary Public Offering And Repurchase Of Common Stock

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment...

IQVIA Announces Senior Secured Credit Facility Transaction To Refinance Existing Indebtedness

IQVIA Announces Senior Secured Credit Facility Transaction To Refinance Existing Indebtedness

IQVIA Inc., a wholly-owned subsidiary of IQVIA Holdings Inc.

IQVIA Launches Commercial Content Management Solution IQVIA™ EPromo

IQVIA Launches Commercial Content Management Solution IQVIA™ EPromo

IQVIA (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced the launch of IQVIA™ ePromo, a new cloud-based content management technology solution.

IQVIA™ Institute For Human Data Science Study: Spending On Cancer Meds In The U.S. Doubled From 2012-2017 - Expected To Double Again By 2022 To $100 Billion

IQVIA™ Institute For Human Data Science Study: Spending On Cancer Meds In The U.S. Doubled From 2012-2017 - Expected To Double Again By 2022 To $100 Billion

The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2018: Innovation, Expansion and Disruption, that spending on cancer drugs in the U.

PruGen Pharmaceuticals Selects IQVIA's OCE Technology Platform To Advance Field Sales And Home Office Effectiveness

PruGen Pharmaceuticals Selects IQVIA's OCE Technology Platform To Advance Field Sales And Home Office Effectiveness

IQVIA™ (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced that PruGen Pharmaceuticals has selected Orchestrated Customer Engagement (OCE), IQVIA's...

IQVIA Holdings Inc. Provides Update On Secondary Offering

IQVIA Holdings Inc. Provides Update On Secondary Offering

IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, announced today that in light of recent market conditions, it and the selling...

IQVIA Response To FDA Statement

IQVIA Response To FDA Statement

IQVIA™ (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry.

IQVIA Announces Pricing Of Secondary Public Offering

IQVIA Announces Pricing Of Secondary Public Offering

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) announced today the pricing of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment...

IQVIA Announces Launch Of Secondary Public Offering And Repurchase Of Common Stock

IQVIA Announces Launch Of Secondary Public Offering And Repurchase Of Common Stock

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) announced today the launch of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment...

IQVIA To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

IQVIA To Present At The Bank Of America Merrill Lynch Health Care Conference On May 15, 2018

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas on Tuesday, May 15, 2018 at...

IQVIA Reports First-Quarter 2018 Results And Raises Full-Year 2018 Revenue Guidance

IQVIA Reports First-Quarter 2018 Results And Raises Full-Year 2018 Revenue Guidance

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2018.

Recordati Selects IQVIA's OCE Technology Platform And OneKey Information Services

Recordati Selects IQVIA's OCE Technology Platform And OneKey Information Services

IQVIA (NYSE:IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, and Recordati SpA today announced a service alliance.

IQVIA™ Institute For Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent In 2017 - Largest Drop In 25 Years

IQVIA™ Institute For Human Data Science Study: U.S. Prescription Opioid Volume Declined 12 Percent In 2017 - Largest Drop In 25 Years

The latest report from the IQVIA™ Institute for Human Data Science found prescription opioid dosage volume — as defined by Morphine Milligram Equivalents (MME) — declined 12 percent in 2017, marking the largest annual drop in more than...

IQVIA Establishes Alliance With MuleSoft To Deliver Innovative Integration Technology To Life Sciences Companies

IQVIA Establishes Alliance With MuleSoft To Deliver Innovative Integration Technology To Life Sciences Companies

IQVIA (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced at the eyeforpharma conference that it has formed a strategic...

IQVIA Forms Alliance With Box To Provide Revolutionary, Cloud-Based Content Management Solutions To The Life Sciences And Healthcare Industries

IQVIA Forms Alliance With Box To Provide Revolutionary, Cloud-Based Content Management Solutions To The Life Sciences And Healthcare Industries

IQVIA™ (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, today announced at the eyeforpharma conference that it has entered into an...

IQVIA Institute For Human Data Science Study: 10 Predictions For Innovation, Spending Drivers And Societal Value Of Medicines That Will Transform Global Healthcare In 2018 And Beyond

IQVIA Institute For Human Data Science Study: 10 Predictions For Innovation, Spending Drivers And Societal Value Of Medicines That Will Transform Global Healthcare In 2018 And Beyond

According to a new report from the IQVIA™ Institute for Human Data Science, the types of medicines being developed, the way technology contributes to health, and how the value of health is calculated are all changing...

Analyst Favorites With Strong Buyback Activity: IQVIA Holdings Ranks As a Top Pick

Analyst Favorites With Strong Buyback Activity: IQVIA Holdings Ranks As a Top Pick

A study of analyst recommendations at the major brokerages shows that IQVIA Holdings Inc is the #50 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity. To make that list, a stock must have repurchased at least 5% of its outstanding shares over the trailing twelve month period.

24 Stocks Hedge Funds Are Loving Right Now

24 Stocks Hedge Funds Are Loving Right Now

Hint: hedge funds love the tech sector no matter what. Here are some of the hottest picks from the hedgies.

IQVIA Reports Fourth-Quarter And Full-Year 2017 Results, Issues First-Quarter And Full-Year 2018 Guidance

IQVIA Reports Fourth-Quarter And Full-Year 2017 Results, Issues First-Quarter And Full-Year 2018 Guidance

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better...

IQVIA To Lead Group To Expand Safety/Efficacy Monitoring Of Regulated Vaccines And Biologics For The FDA Center For Biologics Evaluation And Research

IQVIA To Lead Group To Expand Safety/Efficacy Monitoring Of Regulated Vaccines And Biologics For The FDA Center For Biologics Evaluation And Research

IQVIA Holdings Inc. (NYSE: IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, is announcing a novel alliance with the FDA Center for Biologics...

TheStreet Quant Rating: B (Buy)